A Phase 2a, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of SAGE-217 Oral Solution in the Treatment of Subjects With Essential Tremor
Phase of Trial: Phase II
Latest Information Update: 10 Jan 2018
At a glance
- Drugs SAGE 217 (Primary)
- Indications Essential tremor
- Focus Therapeutic Use
- Sponsors Sage Therapeutics
- 04 Jan 2018 Status changed from active, no longer recruiting to completed.
- 08 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 02 Nov 2017 According to a Sage Therapeutics media release, Top-line results from Part C are expected in 4Q 2017.